OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OPTN
Previous Symbol
CUSIPN/A
Phone267-364-3500
Debt
Debt-to-Equity Ratio0.51
Current Ratio10.44
Quick Ratio10.13
Price-To-Earnings
Trailing P/E Ratio-1.66
Forward P/E Ratio-3.19
P/E GrowthN/A
Sales & Book Value
Annual Sales$47.50 million
Price / Sales8.12
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book2.29
Profitability
EPS (Most Recent Fiscal Year)($5.63)
Net Income$-48,900,000.00
Net MarginsN/A
Return on Equity-67.95%
Return on Assets-41.63%
Miscellaneous
Employees82
Outstanding Shares41,230,000
Market Cap$425.47 million
OptionableNot Optionable
OptiNose (NASDAQ:OPTN) Frequently Asked Questions
What is OptiNose's stock symbol?
OptiNose trades on the NASDAQ under the ticker symbol "OPTN."
How were OptiNose's earnings last quarter?
OptiNose Inc (NASDAQ:OPTN) issued its earnings results on Tuesday, November, 13th. The company reported ($0.61) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.72) by $0.11. The firm earned $1.90 million during the quarter, compared to analyst estimates of $1.57 million. View OptiNose's Earnings History.
When is OptiNose's next earnings date?
What price target have analysts set for OPTN?
3 brokerages have issued 1-year price targets for OptiNose's stock. Their predictions range from $27.00 to $30.00. On average, they anticipate OptiNose's stock price to reach $28.3333 in the next twelve months. This suggests a possible upside of 202.7% from the stock's current price. View Analyst Price Targets for OptiNose.
What is the consensus analysts' recommendation for OptiNose?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptiNose.
What are Wall Street analysts saying about OptiNose stock?
Here are some recent quotes from research analysts about OptiNose stock:
- 1. According to Zacks Investment Research, "OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA. " (8/15/2018)
- 2. Cantor Fitzgerald analysts commented, ": We are initiating research coverage of OPTN stock with an Overweight rating and 12-month PT of $30. We view Xhance as an asset that will create significant share value and allow the company to expand commercial activities into ENT- and allergist-managed medical conditions. We believe OPTN should be able to leverage the proprietary exhalation delivery system (EDS) to develop therapies that fit within the target physician population and could be applicable for other medical uses that could create partnering/out-licensing opportunities." (8/7/2018)
Has OptiNose been receiving favorable news coverage?
News headlines about OPTN stock have trended very positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. OptiNose earned a daily sentiment score of 3.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an effect on the company's share price in the near future.
Who are some of OptiNose's key competitors?
Some companies that are related to OptiNose include Innoviva (INVA), Cambrex (CBM), Enanta Pharmaceuticals (ENTA), G1 Therapeutics (GTHX), Corcept Therapeutics (CORT), The Medicines (MDCO), Theravance Biopharma (TBPH), Spectrum Pharmaceuticals (SPPI), Phibro Animal Health (PAHC), Biohaven Pharmaceutical (BHVN), Nabriva Therapeutics (NBRV), Insmed (INSM), Mirati Therapeutics (MRTX), Myovant Sciences (MYOV) and Portola Pharmaceuticals (PTLA).
Who are OptiNose's key executives?
OptiNose's management team includes the folowing people:
- Mr. Peter K. Miller, CEO & Director (Age 57)
- Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 53)
- Mr. Keith Alan Goldan, Chief Financial Officer (Age 47)
- Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 42)
- Mr. Thomas E. Gibbs, Chief Commercial Officer (Age 46)
When did OptiNose IPO?
(OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.
Who are OptiNose's major shareholders?
OptiNose's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), JPMorgan Chase & Co. (4.55%), JPMorgan Chase & Co. (4.55%), Foresite Capital Management IV LLC (3.54%), Thrivent Financial for Lutherans (3.11%) and BlackRock Inc. (2.61%). Company insiders that own OptiNose stock include Peter K Miller, Robert P O'neil, Sriram Venkataraman and Thomas Edward Gibbs. View Institutional Ownership Trends for OptiNose.
Which institutional investors are selling OptiNose stock?
OPTN stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Wells Fargo & Company MN and TIAA CREF Investment Management LLC. View Insider Buying and Selling for OptiNose.
Which institutional investors are buying OptiNose stock?
OPTN stock was acquired by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Foresite Capital Management IV LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Rice Hall James & Associates LLC, Point72 Asset Management L.P., Massachusetts Financial Services Co. MA and Citadel Advisors LLC. Company insiders that have bought OptiNose stock in the last two years include Peter K Miller, Robert P O'neil and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose.
How do I buy shares of OptiNose?
Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OptiNose's stock price today?
One share of OPTN stock can currently be purchased for approximately $9.36.
How big of a company is OptiNose?
OptiNose has a market capitalization of $425.47 million and generates $47.50 million in revenue each year. The company earns $-48,900,000.00 in net income (profit) each year or ($5.63) on an earnings per share basis. OptiNose employs 82 workers across the globe.
What is OptiNose's official website?
How can I contact OptiNose?
OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]
MarketBeat Community Rating for OptiNose (NASDAQ OPTN)
MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote "Outperform" if you believe OPTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
